Endovascular Engineering, Inc. ("E2") has secured $42 million in an oversubscribed Series B financing to advance its next generation clot removal technology platform for venous thromboembolism (VTE).

Effective dyspnea evaluation in urgent care requires the usage of a systems-based framework for categorizing the differential ...

In the United States alone, 104 million people are at risk of cardiovascular disease, and in a study of those that experienced a heart attack at age 50 or younger, half were not previously seen as ...

Now, research from my lab and others suggests that GLP-1 drugs ... risk of blood clotting as well as deep vein thrombosis and pulmonary embolism. One puzzling finding in our study is the reduced ...

Now, research from my lab and others suggests that GLP-1 drugs ... risk of blood clotting as well as deep vein thrombosis and pulmonary embolism. One puzzling finding in our study is the reduced ...

Now, research from my lab and others suggests that GLP-1 drugs could help treat ... effect in reducing risk of blood clotting as well as deep vein thrombosis and pulmonary embolism. One puzzling ...

Pulmonary embolism (PE) continues to challenge clinicians with ... we have expertise in the cath lab and are the ones to manage critically ill patients with right ventricular (RV) dysfunction," he ...

Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE). Although the Tendvia mechanical thrombectomy system has been validated in pigs, further evidence supporting its ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Mechanical thrombectomy is effective and safe for treating pulmonary embolism (PE).

Endovascular Engineering, Inc. (E2) announced it has secured $42 million in oversubscribed Series B financing to advance its n ...